National Cancer Institute (NCI)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).

3,257 total trials 326 currently recruiting 2051 completed early-phase tilt top decile by trial count

National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.

National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.

Top-decile sponsor footprint

National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

3,257 total, page 25 of 66

COMPLETED Phase 1

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

NCT01729806
COMPLETED

Perspective-taking, and Examining the Clinical Trial Informed Consent Process

NCT01778582
COMPLETED Phase 1

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

NCT01709435
COMPLETED Phase 2

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT01716715
COMPLETED Phase 2

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

NCT01727089
COMPLETED Phase 1

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

NCT01648348
TERMINATED Phase 1

Ruxolitinib for Adult T-Cell Leukemia

NCT01712659
COMPLETED Phase 1

Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer

NCT01711541
COMPLETED Phase 1

Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas

NCT01434602
COMPLETED Phase 1

Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer

NCT01711515
COMPLETED Phase 1

Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

NCT01217450
COMPLETED Phase 1

Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors

NCT01725191
TERMINATED Phase 2

Imaging Studies of Kidney Cancer Using 18F-VM4-037

NCT01712685
COMPLETED Phase 1

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT01642251
COMPLETED

Relationship Stressors in Parents of Children With Cancer or Neurofibromatosis Type 1 (NF1)

NCT01702922
COMPLETED Phase 2

Cabozantinib for Advanced Urothelial Cancer

NCT01688999
COMPLETED Phase 1

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

NCT01683994
TERMINATED Phase 2

Mithramycin for Lung, Esophagus, and Other Chest Cancers

NCT01624090
TERMINATED Phase 1

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

NCT01705340
COMPLETED Phase 2

Pomalidomide for Chronic Graft-versus-Host Disease

NCT01688466
COMPLETED Phase 2

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

NCT01653028
COMPLETED Phase 1

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

NCT01624441
COMPLETED Phase 2

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

NCT01696955
COMPLETED Phase 2

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

NCT01688973
TERMINATED Phase 2

Lenalidomide Maintenance Therapy for Multiple Myeloma

NCT01675141
TERMINATED Phase 2

Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

NCT01681368
COMPLETED

Self-Affirmation and Response to Health Risk Information

NCT01668771
COMPLETED

Validating Pain Scales in Children and Young Adults

NCT01639950
COMPLETED Phase 1

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

NCT01638533
COMPLETED Phase 2

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

NCT01664182
COMPLETED Phase 1

Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation

NCT01447355
COMPLETED Phase 2

Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

NCT01637961
COMPLETED Phase 2

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

NCT01658943
COMPLETED Phase 1

ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer

NCT01675128
COMPLETED Phase 1

Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

NCT01654965
COMPLETED

Collecting Solid Tumor Tissue to Identify New Treatments

NCT01658917
COMPLETED Phase 2

Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma

NCT01604772
COMPLETED

Testing the FLASHE Survey

NCT01661036
COMPLETED

Biomarkers for Breast Cancer Risk in African American Women

NCT01736306
COMPLETED Phase 2

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

NCT01553149
COMPLETED Phase 2

Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery

NCT01623869
COMPLETED Phase 1

Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic

NCT01643278
COMPLETED Phase 2

Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer

NCT01688609
TERMINATED Phase 1

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

NCT01658904
COMPLETED Phase 1

Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma

NCT01593696
COMPLETED Phase 2

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

NCT01614795
COMPLETED Early Phase 1

Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain

NCT01633008
COMPLETED Phase 2

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

NCT01609790
COMPLETED Phase 2

Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus

NCT01447927
TERMINATED Phase 1

High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma

NCT01378481
← Previous Page 25 of 66 Next →

Phase Distribution

PhaseTrial count
Phase 1 1199
Phase 2 1429
Phase 3 193

Therapeutic Areas

Advanced Malignant Solid Neoplasm 67
Refractory Malignant Solid Neoplasm 45
Metastatic Malignant Solid Neoplasm 38
Refractory Multiple Myeloma 35
Prostate Cancer 34
Refractory Lymphoma 33
Advanced Lymphoma 33
Acute Myeloid Leukemia 28
Unspecified Adult Solid Tumor, Protocol Specific 26
Breast Cancer 23

What is open in the National Cancer Institute (NCI) pipeline

326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).

Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).

Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.